Merck Steps Up As AiCuris’ First Development Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck partners with on AiCuris on letermovir and other antiviral candidates for human cytomegalovirus (HCMV), marking the first development deal for the German drug developer, spun out from Bayer in 2006.
You may also be interested in...
New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack
Merck & Co’s investigational anti-CMV therapy letermovir is expected to be filed for approval later this year and could be the first of a new generation of anti-CMV therapies, following top-line Phase III data showing it reduced all-cause mortality in bone marrow transplant patients.
Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral
The North Carolina-based start-up strikes a global deal for a Phase I HIV drug, which will allow it to fund late-stage trials on another lipid-antiviral conjugate.
AiCuris GMBH & Co. KG
With seven molecules in clinical development, another three preclinical compounds approaching the clinic, and a half-dozen discovery programs divided equally between virology and bacteriology, AiCuris is seeking the keys to thwarting viral replication. The start-up has drug candidates targeting herpes simplex virus, human cytomegalovirus and hepatitis C.